Acquisition Impact Potential post-acquisition integration opportunities with Elekta and iCAD assets or customer bases to cross-sell the Xoft system, leveraging the broader brachytherapy portfolio and installed base.

Clinical Expansion Opportunity to pursue expansion in the intraoperative radiation therapy and partial breast irradiation segments, highlighting Xoft’s isotope-free, mobile system that can be adopted in varied clinical settings.

Market Positioning Position as a flexible, FDA-cleared, isotope-free alternative for diverse cancers, appealing to hospitals and clinics seeking streamlined radiation therapy workflows without shielded facilities.

Financial Leverage Leverage the mid-market revenue range and sizable funding history to present scalable procurement or financing options to cancer centers expanding their radiotherapy capabilities.

Strategic Partnerships Target collaborations with oncology device distributors and academic medical centers to demonstrate post-market safety and efficacy data, accelerating adoption and potential upsell into related treatment modalities.